LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Crizotinib | 0.12 | uM | LJP5 | 1 | A23 | 72 | hr | 1401 | 3680 | 3978 | 0.9250 | 0.8990 |
| SK-BR-3 | Crizotinib | 0.12 | uM | LJP5 | 2 | A23 | 72 | hr | 1401 | 3934 | 4213 | 0.9337 | 0.9155 |
| SK-BR-3 | Crizotinib | 0.12 | uM | LJP5 | 3 | A23 | 72 | hr | 1401 | 4296 | 4545 | 0.9450 | 0.9345 |
| SK-BR-3 | Crizotinib | 0.37 | uM | LJP5 | 1 | A22 | 72 | hr | 1401 | 3634 | 3978 | 0.9134 | 0.8832 |
| SK-BR-3 | Crizotinib | 0.37 | uM | LJP5 | 2 | A22 | 72 | hr | 1401 | 4153 | 4213 | 0.9857 | 0.9819 |
| SK-BR-3 | Crizotinib | 0.37 | uM | LJP5 | 3 | A22 | 72 | hr | 1401 | 4075 | 4545 | 0.8964 | 0.8752 |
| SK-BR-3 | Crizotinib | 1.11 | uM | LJP5 | 1 | A21 | 72 | hr | 1401 | 2926 | 3978 | 0.7354 | 0.6307 |
| SK-BR-3 | Crizotinib | 1.11 | uM | LJP5 | 2 | A21 | 72 | hr | 1401 | 3453 | 4213 | 0.8196 | 0.7644 |
| SK-BR-3 | Crizotinib | 1.11 | uM | LJP5 | 3 | A21 | 72 | hr | 1401 | 3781 | 4545 | 0.8317 | 0.7943 |
| SK-BR-3 | Crizotinib | 3.33 | uM | LJP5 | 1 | A20 | 72 | hr | 1401 | 2233 | 3978 | 0.5613 | 0.3627 |
| SK-BR-3 | Crizotinib | 3.33 | uM | LJP5 | 2 | A20 | 72 | hr | 1401 | 2548 | 4213 | 0.6048 | 0.4571 |
| SK-BR-3 | Crizotinib | 3.33 | uM | LJP5 | 3 | A20 | 72 | hr | 1401 | 2513 | 4545 | 0.5528 | 0.4105 |
| SK-BR-3 | Crizotinib | 10 | uM | LJP5 | 1 | A19 | 72 | hr | 1401 | 1018 | 3978 | 0.2559 | -0.1914 |
| SK-BR-3 | Crizotinib | 10 | uM | LJP5 | 2 | A19 | 72 | hr | 1401 | 1214 | 4213 | 0.2881 | -0.0865 |
| SK-BR-3 | Crizotinib | 10 | uM | LJP5 | 3 | A19 | 72 | hr | 1401 | 1487 | 4545 | 0.3271 | 0.0355 |
| SK-BR-3 | BMS345541 | 0.04 | uM | LJP6 | 1 | D06 | 72 | hr | 1401 | 4458 | 4139 | 1.0771 | 1.0973 |
| SK-BR-3 | BMS345541 | 0.04 | uM | LJP6 | 2 | D06 | 72 | hr | 1401 | 4361 | 4095 | 1.0649 | 1.0829 |
| SK-BR-3 | BMS345541 | 0.04 | uM | LJP6 | 3 | D06 | 72 | hr | 1401 | 4190 | 4272 | 0.9807 | 0.9759 |
| SK-BR-3 | BMS345541 | 0.12 | uM | LJP6 | 1 | D05 | 72 | hr | 1401 | 3996 | 4139 | 0.9655 | 0.9555 |
| SK-BR-3 | BMS345541 | 0.12 | uM | LJP6 | 2 | D05 | 72 | hr | 1401 | 4041 | 4095 | 0.9867 | 0.9828 |
| SK-BR-3 | BMS345541 | 0.12 | uM | LJP6 | 3 | D05 | 72 | hr | 1401 | 4423 | 4272 | 1.0353 | 1.0436 |
| SK-BR-3 | BMS345541 | 0.37 | uM | LJP6 | 1 | D04 | 72 | hr | 1401 | 3595 | 4139 | 0.8686 | 0.8275 |
| SK-BR-3 | BMS345541 | 0.37 | uM | LJP6 | 2 | D04 | 72 | hr | 1401 | 3561 | 4095 | 0.8695 | 0.8272 |
| SK-BR-3 | BMS345541 | 0.37 | uM | LJP6 | 3 | D04 | 72 | hr | 1401 | 3936 | 4272 | 0.9213 | 0.9006 |
| SK-BR-3 | BMS345541 | 1.11 | uM | LJP6 | 1 | D03 | 72 | hr | 1401 | 3140 | 4139 | 0.7586 | 0.6759 |